MedTrace Logo

Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam

NCT00229125 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2005-09-29

No results posted yet for this study

Summary

The purpose of this study was to evaluate if the medication Gabapentin, which is not approved for the treatment of alcohol withdrawal, is effective in the treatment of alcohol withdrawal syndrome compared to treatment with Lorazepam.

Conditions

  • Alcohol Withdrawal Syndrome(AWS)

Interventions

DRUG

Gabapentin

DRUG

Lorazepam

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    lead NIH

Principal Investigators

  • Robert J. Malcolm, MD · Medical University of South Carolina

  • Carrie Randall, PhD · Medical University of South Carolina, Center for Drug and Alcohol Programs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-07-31
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00229125 on ClinicalTrials.gov